Cancer Vaccine Eradicates Tumors in Unprecedented Trial

Unprecedented trial results on the NHS show an experimental cancer vaccine, amivantamab, has eradicated tumours in patients with advanced head and neck cancers. This new treatment offers hope to individuals for whom chemotherapy and immunotherapy have failed.

The amivantamab vaccine was administered to 102 patients. Researchers reported that over a third experienced tumour shrinkage, with 15 patients achieving complete eradication. This represents a significant advancement, particularly for a patient group with limited treatment options and a typically poor prognosis.

Developed by Johnson & Johnson, amivantamab works by activating the immune system to attack cancer cells. It also blocks epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) proteins, which are crucial for tumour growth and treatment evasion. The vaccine is administered as a quick, three-weekly injection with minimal reported side effects.

One patient, Carl Walsh, 56, from Birmingham, shared his positive experience. After initial treatments failed, he joined the trial and has since seen significant reduction in swelling and pain, allowing him to return to a normal diet and speech. His quality of life has improved dramatically.

While the trial focused on head and neck cancers not including HPV-positive oropharyngeal squamous cell carcinoma, amivantamab has also shown promise in lung cancer. It was approved for NHS use last year for specific lung cancer patients with a certain genetic mutation. Clinical trials are ongoing worldwide for various other cancers.